Kymera Therapeutics Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Kymera Therapeutics Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation: Delaware
Headquarters city: Watertown
Headquarters state / province: Massachusetts
Headquarters country: United States
Fiscal year end: December
Ticker symbol: KYMR
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001815442
EIN: 81-2992166
Wikidata ID: Q113503520

Board of directors

Follow this board

Bruce Booth · Director
Since 2023
Elena Ridloff · Director
Since 2023
Felix Baker · Director Overboarded
Since 2024
Gorjan Hrustanovic · Director
Since 2023
Jeffrey W. Albers · Director
Since 2023
Joanna Horobin · Director
Since 2023
John Maraganore · Director Overboarded
Since 2023
Julian Baker · Director Overboarded
Since 2024
Leigh Morgan · Director
Since 2023
Mark N. Lampert · Director
Since 2023
Nello Mainolfi · Director · Chief Executive Officer
Since 2023
Pamela Esposito · Director
Since 2023
Victor Sandor · Director
Since 2023

Chief executives

Nello Mainolfi · Chief Executive Officer

Dates unknown

Director election results

Annual meeting of June 24, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

10 of this board's directors also sit on 31 other boards. 31 are in the same sector.

Shared director Other board Same sector +15 more in the list below

Prelude Therapeutics Incorporated Same sector
via Felix Baker, Julian Baker and Victor Sandor
ACADIA Pharmaceuticals Inc. Same sector
via Felix Baker and Julian Baker
BeOne Medicines Ltd. Same sector
via Felix Baker and Julian Baker
Bicycle Therapeutics plc Same sector
via Felix Baker and Julian Baker
DBV Technologies S.A. Same sector
via Felix Baker and Julian Baker
Denali Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Immunic Inc. Same sector
via Elena Ridloff and Mark N. Lampert
Immunocore Holdings plc Same sector
via Felix Baker and Julian Baker
Incyte Corp. Same sector
via Felix Baker and Julian Baker
Kiniksa Pharmaceuticals International plc Same sector
via Felix Baker and Julian Baker
Kodiak Sciences Inc Same sector
via Felix Baker and Julian Baker
Madrigal Pharmaceuticals Inc. Same sector
via Felix Baker and Julian Baker
Neurogene Inc. Same sector
via Felix Baker and Julian Baker
Olema Pharmaceuticals Inc. Same sector
via Gorjan Hrustanovic and Mark N. Lampert
Replimune Group Inc. Same sector
via Felix Baker and Julian Baker
TScan Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
vTv Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
ADC Therapeutics SA Same sector
via Victor Sandor
AbCellera Biologics Inc. Same sector
via Victor Sandor
Agios Pharmaceuticals Inc. Same sector
via John Maraganore
Beam Therapeutics Inc. Same sector
via John Maraganore
City Therapeutics Inc. Same sector
via John Maraganore
Hemab Therapeutics Holdings Inc. Same sector
via John Maraganore
Liquidia Corporation Same sector
via Joanna Horobin
MoonLake Immunotherapeutics Same sector
via Mark N. Lampert
ProKidney Corp. Same sector
via John Maraganore
Rapport Therapeutics Inc. Same sector
via John Maraganore
Sionna Therapeutics Inc. Same sector
via Bruce Booth
Spyre Therapeutics Inc. Same sector
via Jeffrey W. Albers
Takeda Pharmaceutical Company Limited Same sector
via John Maraganore
Tectonic Therapeutic Inc. Same sector
via Bruce Booth

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $172,499,918; 2 purchases by 1 insider
Sold, last 12 months: $465,005,254; 260 sales by 11 insiders

Date	Insider	Transaction	Shares	Price	Value
Oct 1, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Option exercise	+30,000	$2.08	$62,400
Oct 1, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Open-market sale	−3,525	$111.44	$392,826
Oct 1, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Open-market sale	−5,506	$112.42	$618,985
Oct 1, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Open-market sale	−4,876	$113.24	$552,158
Oct 1, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Open-market sale	−7,601	$114.43	$869,782
Oct 1, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Open-market sale	−8,230	$115.40	$949,742
Oct 1, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Open-market sale	−262	$116.12	$30,423
Sep 4, 2026	Adams Brian Officer (Chief Legal Officer)	Open-market sale	−1,209	$115.55	$139,700
Sep 4, 2026	Adams Brian Officer (Chief Legal Officer)	Open-market sale	−3,025	$116.81	$353,350
Sep 4, 2026	Adams Brian Officer (Chief Legal Officer)	Open-market sale	−2,137	$117.57	$251,247
Jul 27, 2026	Rooney Terence Officer (Chief Medical Officer)	Grant or award	+38,000	—	—
Jul 7, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Option exercise	+50,000	$2.08	$104,000
Jul 7, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Open-market sale	−50,000	$119.00	$5,950,000
Jul 1, 2026	Goodman Noah Officer (Chief Business Officer)	Open-market sale	−3,389	$114.29	$387,329
Jul 1, 2026	Nello Mainolfi Director, Officer (Chief Executive Officer)	Option exercise	+80,000	$2.08	$166,400

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Kymera Therapeutics Inc.

Who is the CEO of Kymera Therapeutics Inc.?

Nello Mainolfi is Kymera Therapeutics Inc.'s Chief Executive Officer.

How many directors are on Kymera Therapeutics Inc.'s board?

Kymera Therapeutics Inc.'s board has 13 directors: Bruce Booth, Elena Ridloff, Felix Baker, Gorjan Hrustanovic, Jeffrey W. Albers, Joanna Horobin, John Maraganore, Julian Baker, Leigh Morgan, Mark N. Lampert and 3 others.

Are Kymera Therapeutics Inc. insiders buying or selling shares?

Over the last 12 months, Kymera Therapeutics Inc. insiders bought $172.5 million of shares in 2 purchases and sold $465.0 million of shares in 260 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Kymera Therapeutics Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="kymera-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.